Dishman Carbogen Amcis Ltd. (DCAL) Share Price Falls 9.27%: Price Action, Valuation and Sector View

Dishman Carbogen Amcis Ltd. traded at Rs 172.75, down 9.27% today, with a market capitalisation of Rs 2,985.15 crore as the small-cap pharma stock emerged as a top decliner.

Dishman Carbogen Amcis Ltd. Share Price fell to Rs 172.75 on 17 August 2026, down 9.27% from the previous close of Rs 190.40, taking the company’s market capitalisation to Rs 2,985.15 crore. That made the stock one of the notable top decliners in early trade and pushed Dishman Carbogen Amcis Ltd. Share Price Today into the list of closely watched small-cap moves in the Indian stock market.

The session data shows a clear intraday slide rather than a brief fluctuation. The stock opened at Rs 180.85, which also stood as the day’s high, and then moved lower to Rs 172.75, the day’s low, indicating sustained selling pressure through the morning. For investors tracking Dishman Carbogen Amcis Ltd. Stock News, the supplied data confirms the price event itself but does not establish a company-specific catalyst behind the decline.

The move is relevant because it cleared the event filter for a Small Cap stock under the workflow’s price fall framework. Volume also put the decline on the radar: BSE volume stood at 3,406 shares, NSE volume at 1,37,981 shares, and total traded volume at 1,41,387 shares, with turnover of Rs 0.06 crore in the supplied exchange snapshot. In this Univest market update, the focus is on what today’s price action shows, how the valuation reads against the pharmaceuticals benchmark, and what the peer set says about relative positioning.

Dishman Carbogen Amcis Ltd. (DCAL) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 172.75
Previous Close	Rs 190.4
Today's Change	Rs -17.65 (-9.27%)
Day Open	Rs 180.85
Day High	Rs 180.85
Day Low	Rs 172.75
Current Volume (BSE)	3,406
BSE Traded Volume	3,406
NSE Traded Volume	1,37,981
Combined NSE + BSE Volume	1,41,387
Turnover	Rs 0.06 crore
Market Capitalisation	Rs 2,985.15 crore
Market Cap Category	Small Cap

Dishman Carbogen Amcis Ltd. (DCAL) traded at Rs 172.75. versus the previous close of Rs 190.4, a fall of 9.27%. The stock opened at Rs 180.85, reached Rs 180.85, touched Rs 172.75. Reported volume was 3,406.

Dishman Carbogen Amcis Ltd. (DCAL) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 2,985.15 crore
P/E Ratio	184.72x
P/B Ratio	0.45x
ROE	-2.89%
ROCE	-0.26%
EPS	Rs 1.03
Dividend Yield	0%

Dishman Carbogen Amcis Ltd. was valued at a P/E ratio of 184.72x, a P/B ratio of 0.45x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 1.03, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Dishman Carbogen Amcis Ltd. Fundamental Analysis starts with a mixed picture: the company is sizeable within its industry by market capitalisation, yet several profitability metrics remain weak. Dishman Carbogen Amcis Ltd. Market Cap stands at Rs 2,985.15 crore, which places it at the top end of the supplied same-industry benchmark set by market value. However, size on its own does not resolve questions around earnings quality, return ratios and current valuation multiples.

The stock is trading at a P/E ratio of 184.72, a level that stands out immediately when paired with earnings per share of 1.03. EPS indicates the earnings attributable to each outstanding share, and the relatively low EPS alongside a triple-digit P/E means the market price remains high relative to reported earnings. By contrast, the P/B ratio is 0.45, which is below 1 and shows that the stock price is trading below its accounting book base on this metric. That creates an unusual combination: a high earnings multiple but a low book-value multiple.

Return metrics remain soft. ROE is -2.89%, which means shareholder equity did not generate a positive return in the supplied period, while ROCE is -0.26%, indicating capital employed also did not produce a positive operating return. In stock analysis terms, that weakens the fundamental backdrop behind investor enthusiasm and makes today’s price fall easier to understand as a market move that is consistent with cautious assessment of profitability.

Dividend yield is 0, which means the current data does not show a cash payout yield attached to the share price. That matters for investors looking at total return composition, because the investment case is not being supported by an indicated dividend stream in the supplied numbers. Overall, Dishman Carbogen Amcis Ltd. Share Price is drawing attention because the company combines a large small-cap market value with a high P/E, a very low P/B and negative ROE and ROCE. For Univest readers, that makes the stock’s current positioning more about balancing valuation signals than drawing simple conclusions from a single ratio. The next step is to place those numbers against the broader Healthcare and Pharmaceuticals & Drugs benchmark.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	184.72x
Benchmark Median P/E	26.47x
Benchmark Average P/E	40.28x
Benchmark P/E Range	2.98x to 361.02x
Company P/B Ratio	0.45x
Benchmark Median P/B	1.77x
Company ROE	-2.89%
Benchmark Median ROE	9.91%
Company ROCE	-0.26%
Benchmark Median ROCE	12.79%
Company Market Capitalisation	Rs 2,985.15 crore
Benchmark Median Market Cap	Rs 137.8 crore

Dishman Carbogen Amcis Ltd. (DCAL) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Dishman Carbogen Amcis Ltd. (DCAL) has a P/E ratio of 184.72x, which is above the benchmark median of 26.47x, a difference of +597.85%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Dishman Carbogen Amcis Ltd. (DCAL) has a ROE of -2.89%, which is below the benchmark median of 9.91%, a difference of -129.16%. Dishman Carbogen Amcis Ltd. (DCAL) has a ROCE of -0.26%, which is below the benchmark median of 12.79%, a difference of -102.03%.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Dishman Carbogen Amcis Ltd. operates in the Healthcare sector and Pharmaceuticals & Drugs industry, and the same-industry benchmark gives a useful frame for today’s move. The benchmark scope covers 139 companies, which is broad enough to show where the stock sits on valuation and profitability relative to listed peers in the same line of business.

The sharpest contrast appears in P/E. Dishman Carbogen Amcis Ltd. carries a company P/E of 184.72, while the benchmark median is 26.47 and the benchmark average is 40.28 across 105 companies with P/E data. The benchmark range runs from 2.98 to 361.02, so the stock is still within the industry range, but it is far above both the median and the average. That means Dishman Carbogen Amcis Ltd. Share Price is being valued at a much richer earnings multiple than the typical pharmaceuticals peer in the supplied comparison set.

P/B tells a different story. The company’s P/B is 0.45, whereas the benchmark median is 1.77 and the benchmark average is 2.33 across 138 companies. The range spans from -21.33 to 27.19, and Dishman Carbogen Amcis Ltd. sits below both the median and average on this metric. In other words, the stock looks inexpensive relative to book value even while it looks expensive relative to earnings.

Profitability metrics also lag the benchmark. Company ROE is -2.89% versus a benchmark median of 9.91% and average of 7.3%. Company ROCE is -0.26% versus a benchmark median of 12.79% and average of 14.83%. On market value, though, the company stands well above the industry’s Rs 137.8 crore median and Rs 481.52 crore average, and matches the benchmark maximum market capitalisation of Rs 2,985.15 crore. For Univest, this sector view suggests that the market is pricing Dishman Carbogen Amcis Ltd. as a large listed pharmaceuticals name, but its returns profile currently sits below the industry norm.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Beta Drugs Ltd.	BETA	2,827.67	68.16	6.74	18.65	22.17
Hikal Ltd.	HIKAL	2,686.72	0	2.26	15.22	16.15
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,645.37	46.15	1.77	-0.78	8.31
Fredun Pharmaceuticals Ltd.	FREDUN	2,559.68	58.41	8.73	11.42	13.15
Solara Active Pharma Sciences Ltd.	SOLARA	2,465.73	0	1.93	17.23	15.34

Dishman Carbogen Amcis Ltd. (DCAL) has a P/E ratio of 184.72x compared with the displayed peer median of 46.15x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 15.34%, providing a capital-efficiency comparison. Dishman Carbogen Amcis Ltd. (DCAL) has a market capitalisation of Rs 2,985.15 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Dishman Carbogen Amcis Ltd. can also be assessed against listed peers clustered near it by sector and market value. The peer set shows that its market capitalisation of Rs 2,985.15 crore is above Beta Drugs Ltd. at Rs 2,827.67 crore, Hikal Ltd. at Rs 2,686.72 crore, Ind-Swift Laboratories Ltd. at Rs 2,645.37 crore, Fredun Pharmaceuticals Ltd. at Rs 2,559.68 crore and Solara Active Pharma Sciences Ltd. at Rs 2,465.73 crore. That reinforces its relative scale in this peer basket.

On valuation, the company’s P/E of 184.72 is higher than Beta Drugs at 68.16, Ind-Swift Laboratories at 46.15, Fredun Pharmaceuticals at 58.41, Venus Remedies at 20.56 and NGL Fine-Chem at 37.4. It is also above Sai Parenteral’s at 171. This means Dishman Carbogen Amcis Ltd. Share Price is trading at one of the richest earnings multiples in the supplied peer group.

P/B moves the other way. Dishman Carbogen Amcis Ltd. is at 0.45, below Hikal at 2.26, Ind-Swift at 1.77, Fredun at 8.73, Solara at 1.93, Sai Parenteral’s at 3.13, Panacea Biotec at 2.9, Venus Remedies at 3.48, NGL Fine-Chem at 6.15 and Beta Drugs at 6.74. That makes it one of the cheapest stocks in the set on book value.

Returns remain the weaker side of the comparison. ROE at -2.89% trails Beta Drugs at 18.65%, Hikal at 15.22%, Fredun at 11.42%, Solara at 17.23%, Sai Parenteral’s at 13.9%, Venus Remedies at 9.85% and NGL Fine-Chem at 27.9%. It is lower than Ind-Swift’s -0.78% and below Panacea Biotec’s 0 as well. ROCE at -0.26% is also below Beta Drugs at 22.17%, Hikal at 16.15%, Ind-Swift at 8.31%, Fredun at 13.15%, Solara at 15.34%, Sai Parenteral’s at 12.97%, Panacea Biotec at 5.36%, Venus Remedies at 7.89% and NGL Fine-Chem at 33.91%. For Univest readers, the peer picture is straightforward: scale is strong, book-value valuation is low, but profitability and capital efficiency trail most of the comparison set.

Why Investors Are Watching Dishman Carbogen Amcis Ltd.

Dishman Carbogen Amcis Ltd. Share Price is being watched because today’s decline is large enough to stand out in market news, while the underlying numbers create a mixed analytical picture. The stock is a small-cap name by classification but one of the larger companies within its same-industry benchmark by market capitalisation. That combination naturally draws attention when a sharp same-day price fall appears on the screen.

• Price action: The stock fell 9.27% or Rs 17.65 to Rs 172.75 from a previous close of Rs 190.40.
• Intraday pattern: It opened at Rs 180.85, which also marked the day’s high, and then slipped to the low of Rs 172.75.
• Volume context: Total traded volume reached 1,41,387 shares, with 1,37,981 on NSE and 3,406 on BSE.
• Fundamentals: P/E is 184.72, P/B is 0.45, ROE is -2.89%, ROCE is -0.26%, EPS is 1.03 and dividend yield is 0.
• Sector positioning: The company’s P/E is above the industry median and average, while its P/B is below both benchmark levels.

What investors should monitor next is whether Dishman Carbogen Amcis Ltd. Stock News develops around company-specific disclosures, and whether future financial performance improves enough to change the gap between valuation and returns. Univest believes the key watchpoints remain earnings quality, capital efficiency and how the stock behaves relative to peers in the Pharmaceuticals & Drugs space rather than any single intraday print.

About Dishman Carbogen Amcis Ltd.

Dishman Carbogen Amcis Ltd. is a listed Indian company tracked under the Healthcare sector and the Pharmaceuticals & Drugs industry. In market structure terms, that places it among healthcare and pharma businesses whose share prices are often assessed through earnings multiples, return ratios and peer benchmarking within the broader Indian stock market.

Based on the supplied company context, the clearest verified positioning is its industry placement and market size. With a market capitalisation of Rs 2,985.15 crore, Dishman Carbogen Amcis Ltd. stands at the upper end of the same-industry benchmark by market value, even though it is classified as a Small Cap for the event framework used here. That makes it a notable name within its listed industry basket.

For readers following Dishman Carbogen Amcis Ltd. Share News, the most relevant business context available in the verified data is its participation in Pharmaceuticals & Drugs, a segment where listed peers are frequently compared on P/E, P/B, ROE and ROCE. Today’s market move therefore matters not only as a standalone share price update, but also as a signal that the stock remains actively monitored within the healthcare and pharma universe. Univest will continue to frame the company through this sector and valuation lens unless fresh company disclosures change the analytical picture.

Track Dishman Carbogen Amcis Ltd. Share Price on Univest

Use Dishman Carbogen Amcis Ltd. (DCAL) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Readers who want to follow Dishman Carbogen Amcis Ltd. Share Price more closely can use Univest to track live share price moves, daily highs and lows, 52-week levels, market capitalisation, valuation ratios and broader stock analysis. Univest also helps users monitor sector context, peer comparison, shareholding pattern when available, and important market insights around price action in NSE and BSE-listed stocks.

For investors researching Dishman Carbogen Amcis Ltd. Share Price Today or looking for Dishman Carbogen Amcis Ltd. Latest News, the goal is not to react to a single move in isolation, but to place price behaviour alongside fundamentals, industry benchmarks and relative performance across comparable healthcare names.

Frequently Asked Questions

Why is Dishman Carbogen Amcis Ltd. Share Price falling today?

Ans. Dishman Carbogen Amcis Ltd. Share Price fell 9.27% to Rs 172.75 from the previous close of Rs 190.40. The supplied data confirms the sharp price fall and intraday weakness, but it does not establish a company-specific catalyst behind today’s decline.

What is Dishman Carbogen Amcis Ltd. Share Price Today?

Ans. Dishman Carbogen Amcis Ltd. Share Price Today is Rs 172.75 in the supplied market snapshot. The stock was down Rs 17.65 on the day, after opening at Rs 180.85 and trading within an intraday range of Rs 172.75 to Rs.

How much did Dishman Carbogen Amcis Ltd. stock fall today?

Ans. The stock declined by Rs 17.65, or 9.27%, compared with its previous close of Rs 190.40. That move was significant enough for the company to be captured under the workflow’s Small Cap price fall event classification.

What does today’s intraday price action show for Dishman Carbogen Amcis Ltd.?

Ans. The stock opened at Rs 180.85, which also remained the day’s high, and then slipped to Rs 172.75, the day’s low and current price. This pattern points to sustained morning weakness rather than a recovery-led or range-bound trading session.

What was the trading volume in Dishman Carbogen Amcis Ltd. today?

Ans. Total traded volume stood at 1,41,387 shares in the supplied data, including 1,37,981 shares on NSE and 3,406 shares on BSE. The turnover figure in the exchange snapshot was Rs 0.06 crore, showing active participation around the decline.

What is the market capitalisation of Dishman Carbogen Amcis Ltd.?

Ans. Dishman Carbogen Amcis Ltd. has a market capitalisation of Rs 2,985.15 crore. Although the event framework classifies it as a Small Cap stock, its market value is high relative to the broader same-industry benchmark included in the supplied data.

Is Dishman Carbogen Amcis Ltd. expensive or cheap on valuation metrics?

Ans. Valuation looks mixed in the supplied numbers. The stock trades at a P/E of 184.72, above the industry median of 26.47 and average of 40.28, while its P/B of 0.45 is below the industry median of 1.77 and average of.

How profitable is Dishman Carbogen Amcis Ltd. based on the latest ratios?

Ans. The profitability ratios in the supplied snapshot are weak. ROE is -2.89% and ROCE is -0.26%, both below the same-industry benchmark medians of 9.91% and 12.79%, indicating returns remain behind many listed pharmaceuticals peers.

What are the key fundamental metrics for Dishman Carbogen Amcis Ltd.?

Ans. Key metrics include market capitalisation of Rs 2,985.15 crore, P/E of 184.72, P/B of 0.45, ROE of -2.89%, ROCE of -0.26%, EPS of 1.03 and dividend yield of 0. These numbers frame today’s stock analysis.

How does Dishman Carbogen Amcis Ltd. compare with pharma peers?

Ans. Dishman Carbogen Amcis Ltd. has a larger market capitalisation than peers like Beta Drugs, Hikal and Ind-Swift Laboratories in the supplied list. However, its P/E is higher than most peers, while ROE and ROCE trail several comparable pharmaceuticals companies.